ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

spinosad

Also written as “Spinosad”, “APT-001 topical ophthalmic ointment (spinosad)” and “DE-105 ophthalmic solution”.

Its studies are mostly in Blepharitis · Lice Infestations · Epilepsy, led by 4 companies.

Drug pageSpinosad: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Aug 6, 20128 company-led studies, 1 open or runningNext primary completion: Jan 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
ParaPROits history only40 open or runningphase 4since Aug 6, 2012Oct 15, 2007none ahead
Aperta Biosciences21 open or runningphase 2since Dec 3, 2024Dec 3, 2024Jan 2027phase 2 · NCT07904767
Santen Pharmaceuticalits history only10 open or runningphase 2since Sep 30, 2009Sep 30, 2009none ahead
Takedaits history only10 open or runningphase 1since Jul 9, 2015Jul 9, 2015none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Aperta Biosciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 3, 2024First study: phase 2 study in BlepharitisFirst studyNCT06720896 · 66 enrolled · Guatemala
  2. Oct 23, 2026Phase 2 study in BlepharitisNCT07904767 · 15 planned · Guatemala

Ahead

  1. Jan 2027Primary completion: phase 2 study in BlepharitisNCT07904767

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Nicotinic acetylcholine receptor agonist”ChEMBL 37, by rule

Studies

All 2 Aperta Biosciences leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07904767Blepharitis · Guatemala2Not yet recruitingJan 202715
NCT06720896Blepharitis · Guatemala2CompletedJul 13, 202666

How it is read

Names in the registry

  • “Spinosad”, 4 entries
  • “APT-001 topical ophthalmic ointment (spinosad)”, 2 entries
  • “DE-105 ophthalmic solution”, 2 entries
  • “[18F]MNI-792 (tracer)”, 1 entry
  • “spinosad”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.